Replies to post #8245 on BioAdaptives Inc (BDPT)

[powerbattles]

De nada bro. Yesterday, I mentioned that I would gather all the essential information for everyone's review. I'm uncertain about the best approach to begin, but I recall that some time ago, I shared a link below for everyone to read. Given the substantial amount of reading material, I understand that some may read everything, while others might not, in order to grasp the complete picture. I'll provide that link below once more so that we can collectively delve into the heart of the matter.

Stem cell research can revolutionize medicine, more than anything since antibiotics.” ~Ronald P. Reagan
THE SCIENCE—BACKGROUND & STUDIES—BEHIND PRIMICELL® AND ITS DERIVATIVES GENESIS

https://www.livestockimpact.com/pages/primicell-study

The first part of this story says over seven years ago a team of world-class Medical Doctors specializing in pharmaceutical testing and toxicology were brought together to take testing of the product PrimiCell® to the next level.

"They are a retired Harvard Medical School professor",
That is Dr: Edward E. Jacobs Chairman & Chief Executive Officer.

"The next member is a Medical Doctor from China with a PhD in toxicology. He is an associate professor University of Albany."
That is Dr. Yaguang Liu Director.

"The third member is a Medical Doctor from Saint Petersburg, Russia. She has worked for over 20 years in the pharmaceutical industry and human clinical trials."

This individual is the one I've been trying to find for quite some time. I'm grateful to pinkslipjunkie for posting about the Key Company Executive, which illuminated the path for me to connect all the pieces together. So, we now have Antonina Nabokova as BDPT's medical advisor. Now, let's closely examine who she is and delve into the reasons why she's willing to stake her reputation by serving as the medical advisor for a small company with a stock trading at fractions of a cent.

Who Is Antonina Nabokova?

Antonina Nabokova works as a Head of Representative Office, Clinical Operations Director at Syneos Health, which is a Research & Development company with an estimated 28.8 K employees; and founded in 1998. They are part of the Clinical Operations team within the Medical & Health Department and their management level is Director. Antonina graduated from Pavlov Medical University in 1987 and is currently based in Russia. They used to work at Worldwide Clinical Trials and Evidence CPR and have used the following emails: @synteract.com, @evidence-cpr.com.

Antonina's Workplace



Headquarters: 1030 Sync St, Morrisville, North Carolina, 27560, United States
Employees: 28.8k
Revenue: $5.4B
Syneos Health® (Nasdaq: SYNH) $42.51 At close: August 22 04:00PM EDT

Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. Syneos translates unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. Syneos brings together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together Syneos shares insights, uses the latest technologies and applies advanced business practices to speed customers' delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment...
https://www.datanyze.com/people/Antonina-Nabokova/594043333

More details Previous Work Experience Biography for Antonina Nabokova, Syneos Health. Read link below.
https://www.linkedin.com/in/antonina-nabokova-23560730/


Jun Gu
Medical Advisor
Dr. Jun Gu is a Professor at the School of Health Professions (SHP) and is a Program Director for the Cytogenetic Technology (CGT) Program. He received his Bachelor's degree in Medicine from the School of Medicine, Zhejiang University in 1989. He completed his surgical residency in Hangzhou Red Cross Hospital in 1992. He later received his Master's degree in Environmental Science with an emphasis in Genetic Toxicology from the School of Public Health, University of Texas Health Science Center in Houston and subsequently a Doctor of Philosophy from Trident University in Healthcare Management. He was the last graduate student of Dr. T.C. Hsu, who discovered hypotonic effect for modern cytogenetics. Dr. Gu holds a specialty clinical cytogenetics certification from ASCP. He joined MD Anderson Cancer Center in 1994 and has worked in both clinical and academic environments. Dr. Gu has taught over 15 courses to CGT, DG, and SHP students. He is also serving as a member of the institutional Education Resources Committee (ERC) and Alumni & Faculty Association Steering Committe at the MD Anderson Cancer Center. Dr. Gu has 35 publications in peer-reviewed journals, 85 abstracts, and 60 oral and poster presentations.
https://faculty.mdanderson.org/profiles/jun_gu.html

As you can see, we're backed by an exceptional team. These scientists possess extensive clinical research experience with major global companies and have dedicated the past seven years to working on PrimiCell®—and that's no coincidence. Dr. Jun Gu and Dr. Antonina Nabokova both became part of BDPT's team because they wanted to be associated with a successful venture.
Let's also acknowledge Dr. Jacobs, who assumed control of the company in 2019. He promptly initiated financial auditing and elevated the company to SEC fully-reporting status. In just a few short years, he's managed to introduce numerous products to the market. Clearly, these individuals together have been executing a well-laid game plan over the past decade.

Additionally, there's an impending IPO for a new company targeting Myopia and Presbyopia drug treatments for both human and animal markets, which hold tremendous potential. The global stem cells market is expansive, and PrimiCell® is an exceptional product that hasn't yet market to reached its full market potential. Now is the right moment for them to put their plans into definitive action.

After waiting for many months, we're on the brink of the spin-off announcement and a multitude of other significant news announcement. Will you abandon ship and miss out on this once-in-a-lifetime opportunity, or will you choose to wait, exercising patience, because you recognize that good things will eventually come your way, rewarding your patience?

CONFIRMATION—MULTIPLE STUDIES FOR MULTIPLE HUMAN CONDITIONS ALL GENERATING SUPERIOR OUTCOMES

Human Clinical Trial. The Advisory Team developed a versatile protocol that would be acceptable in the United States, Europe and Asia. An outside Clinical Data Management company was hired to do the randomization and control the data including the data collection process. Protocols for a Human Clinical trial were written and an IRB was approved. The trial was a randomized, double blind; placebo controlled Human Clinical Trial managed by an outside Clinical Data Management

Link below: Key Company Executives BioAdaptives Inc.
https://www.wsj.com/market-data/quotes/BDPT/company-people/executive-profile/185649189

Edward E. Jacobs
Chairman & Chief Executive Officer
Robert W. Ellis
President & Chief Financial Officer
Charles Townsend
Chief Operating Officer & Director
Jun Gu
Medical Advisor
Antonina Nabokova
Medical Advisor
Yaguang Liu
Director

Dr. Jacobs, Director and CEO said, "We are very pleased to again be an SEC fully-reporting Company
https://www.send2press.com/wire/bioadaptives-inc-announces-return-to-fully-reporting-and-appointment-of-president/

The global stem cells market is projected to grow from $11.90 billion in 2021 to $27.65 billion in 2028 at a CAGR of 12.8% in the forecast period [2021-2028]... Read More at:- https://www.fortunebusinessinsights.com/stem-cells-market-105138
https://www.fortunebusinessinsights.com/stem-cells-market-105138